A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients With Diabetic Kidney Disease
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Monlunabant (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Inversago Pharma
Most Recent Events
- 12 Sep 2024 Status changed from active, no longer recruiting to completed.
- 02 Sep 2024 Planned End Date changed from 24 Sep 2024 to 4 Sep 2024.
- 08 May 2024 Status changed from recruiting to active, no longer recruiting.